Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 28;3(2):e00583-17. doi: 10.1128/mSphere.00583-17

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

PMC Copyright notice

FIG 6 — Shigella-specific serum IgG and IgA endpoint titers in guinea pigs immunized intranasally with S. flexneri 2a Invaplex_NAT or Invaplex_AR. Groups of guinea pigs (n = 6/group) were immunized intranasally on days 0, 14, and 28. Dose amounts of S. flexneri 2a Invaplex_NAT and S. flexneri 2a Invaplex_AR are indicated on the x axis. Guinea pigs were challenged on day 49 with S. flexneri 2a strain 2457T. Blood was collected on days 0, 28, 40, and 63 and analyzed by ELISA for anti-S. flexneri 2a LPS (top panels) or IpaB (middle panels) or IpaC (bottom panels) serum IgG (left panels) and IgA (right panels) endpoint titers. The mean endpoint titer + 1 standard error of the mean on day 40 is plotted, and significant differences (two-way analysis of variance; P < 0.05) between dose-matched groups are indicated with an asterisk.